Background: Autologous dentritic cell immunotherapy has been proven effective in treating
Introduction

Background
Glioblastoma multiforme (GBM) remains one of the most lethal tumors despite recent treatment advances in neuro-oncology. Treatment with combination of surgical resection, radiotherapy and chemotherapy is standard of care and provides a statistically significant survival benefit with minimal additional toxicity when compared to treatment with resection and radiotherapy alone 1 . Despite the latter though, overall survival remains very poor with median overall survival of 14.6 months, 2 year survival of 26.5% and 5 year survival of 9.7% 1 . Different approaches are currently being investigated with immunotherapy being one of the most appealing and currently under intense investigation. Immunotherapy aims at boosting the patients' immune system to recognize and attack tumor cells.
The infiltration of both animal and human tumors by lymphocytes is known for more than a century now and in the 1960s a possible relation between infiltration and prognosis was considered 2, 3 . Hamlin was the first to show the relation between lymphocytic infiltration and prognosis in patients with breast cancer 4 . Other studies showed that the majority of cells infiltrating tumors were T cells (80%) and that there was positive correlation between the degree of lymphocytic infiltration of primary tumors and the absence of metastases 5 . Bertrand and Mannen, in 1960, were the first to report infiltration of glioma microenvironment by lymphocytes 6 , followed by Lucio Palma who showed that glioblastoma patients with definite lymphocytic infiltration had significantly longer postoperative survival 7 .
The presence of the blood-brain barrier, the unique lymphatic drainage of the central nervous system (CNS) 8 , as well as the distinct and localized actions of the microglia create an immunologically challenging environment within which brain tumors grow, escaping regular immune surveillance observed in peripheral tissues 9 . Additionally, it has been shown that in patients with GBMs, there is under-expression of immunostimulatory MHC class I molecules and overexpression of suppressive surface proteins (PD-L1, FasL) and cytokines (IL-10, TGF-b, CCL) which stimulate the accumulation of T regulatory cells and myeloid derived suppressor cells. This leads to impaired proliferation and activation of cytotoxic lymphocytes.
Thus accumulation of natural killer and regulatory T cells causes leukopenia and immunological compromise [10] [11] [12] ( Figure 1 ).
Evidence that the "immunologically privileged" environment of the central nervous system can be overcome and that an immune response against brain tumors can be generated by vaccination with cytokine-producing tumor cells was first described almost twenty years ago. In this study it was shown that tumor-bearing mice had increased overall survival (OS)
following subcutaneous vaccination with genetically engineered tumor cells. Interestingly, in the same study, they concluded that, unlike tumors outside the CNS, where the presence of both CD4 and CD8 cells is necessary for an effective response, relative depletion of CD4 cells with increased CD8 cells is associated with better outcome with CNS tumors 13 . A significant number of other preclinical studies on various grades of tumors showed similar results with reports of an increase in the OS of animals injected with tumor cells previously cultured with antigen presenting cells 14, 15 . Notably, even complete resolution was reported in some cases 16 .
The above observations, combined with the need for a treatment that is both patient 
Objectives
In this study we aim to review the literature and identify all studies reporting lymphocytic infiltration of the tumor microenvironment following peripheral (subcutaneous or intradermal) vaccination with antigen pulsed DCs for the treatment of intracranial highgrade gliomas (HGGs). Additionally we aim to present the evidence relating to the importance of lymphocytic infiltration in human gliomas. Table 1 .
Methods
General Characteristics of included studies
Three of the above studies took place in the U.S.A (42.8%), one in Taiwan (14.2%), one in Germany (14.2%), one in Australia (14.2%) and one in Japan (14.2%). Four studies were phase I (57.1%), two were phase I/II (28.5%) and one prospective study (14.2%). The number of patients included varied from 12 22 to 24 23 with the mean age varying from 44.7 24, 25 to 51 26, 27 . The vaccination was administered intradermally (ID) in 5 out of 7 studies (71.4%), subcutaneously (SC) in 1 (14.2%) and either intradermally (ID) or intrathecally (IT) in one (14.2%).
In 6 out of 7 studies the vaccine was produced with tumor antigens pulsed with dendritic cells (DC) that were harvested from the patients' peripheral circulation (85.7%), whilst in 1 the vaccine was produced from tumor cell cultures infected with Newcastle Disease Virus 28 (14.2%).
Treatment protocols
The reviewed studies used different inclusion and exclusion criteria, treatment protocols and tumor infiltration identification techniques. Walker included patients with surgically accessible malignant glioma (WHO grade III or IV), with ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2 and absence of other significant disease or pregnancy. There was no specific treatment protocol followed prior to vaccination and patients could receive the vaccine with or without chemotherapy or radiotherapy following surgery 27 . Yamanaka, included patients with HGGs and Karnofsky scores varying from 30 to 80 who received vaccination following radiological confirmation of disease progression 23 . Steiner, studied patients with Karnofsky scores greater than 60 all of whom had undergone maximum tumor resection and radiotherapy before receiving the vaccine 28 . A similar protocol was used in the study of Liau which included GBM patients receiving surgical resection and external beam radiotherapy prior to vaccination 22 . In the study of Prins, the "Stupp" protocol was applied, comprising of surgical resection and concomitant temozolimide chemo radiation, prior to the vaccination 26 . Lastly, Chang, recruited patients with newly diagnosed or recurrent HGGs, newly diagnosed patients received surgical resection with radiation therapy whereas patients with recurrent gliomas were treated solely with surgical resection 24 .
Immunohistochemical analysis
Similar immunohistochemical techniques were used in all studies to identify tumor microenvironment infiltrating lymphocytes. Serial paraffin sections were cut and stained with antihuman antibodies against CD3, CD8, CD4, CD45, CD45RO and transforming growth factor-b2 in the study of Liau 22 ; versus p53, glial fibrillary acidic protein (GFAP), nestin, CD3, CD4 and CD8 in the study of Chang 24 ; versus CD8, CD45RO and mouse anti-human in the study of Walker 27 ; versus CD3, CD4, CD8, CD20 and CD56 in the study of Yamanaka 23 ;
versus CD3 and CD8 for the study of Prins 26 ; versus CD8, EGFR (epidermal growth factor) type III deletion, neurofilament protein, GFAP, platelet endothelial cell adhesive molecule in the study of Steiner 28 ; and CD8, CD45RO, CD20 and CD56 for the study of Yu 25 . (Table 2) .
Lymphocytes infiltrating tumor microenvironment
The presence of tumor infiltrating lymphocytes (TILs) and the significance of it was analyzed to various degrees in the included studies. Tumor samples were collected following radiologically proven progression/recurrence and analyzed with immunohistochemistry as mentioned above. Three studies (42.8%) reported presence of TILs in the post-vaccination specimens that were not present in the pre-vaccination samples examined 25, 29, 30 , whereas the remaining 4 (57.2%) reported increase (to various extents) in the numbers of pre-existing lymphocytes following vaccination.
To summarize the specifics, Yu, reported the presence of cytotoxic CD8 lymphocytes as well as the memory CD45RO cells that were not present prior to vaccination in 3 out of 6 patients (50%) who underwent re-operation for tumor progression 25 . Liau reported a robust T-cell infiltration in 4 out of 8 patients (50%) who underwent re-operation, mainly consisting of CD8 and CD45RO and to a lesser degree CD4 helper cells 29 . Similar results were published by Yamanaka with a significant accumulation of CD8 and CD4 tumor infiltrating cells in 2 out of 7 (28.6%) patients following vaccination, while no such increase was observed in five non-vaccinated patients who underwent re-operation 30 . An increase in the number of already pre-existing infiltrating CD8 and CD45RO cells, in all 4 patients undergoing re-operation, was detected by Walker 27 . Steiner also reported an up to six-fold increase in CD8 cytotoxic cells in vaccinated patients compared to very low numbers in the non-vaccinated group 28 .
Interestingly, Chang, observed two major changes in tumor samples received pre-and post-vaccination. Firstly, a shift from perivascular to relatively diffuse TIL infiltration following vaccination and in addition a reversal in the CD4 and CD8 ratio with an increase in the number of CD8 TILs 24 . Lastly, Prins, described increased infiltration with CD3 and CD8
lymphocytes following dendritic cell vaccination in patients that had undergone re-operation for progression 26 .
Clinical outcome and correlation with tumor microenvironment infiltration
Most of the studies included here were originally designed to assess the feasibility and safety of the treatment. Most authors agreed that there was a benefit in terms of OS and progression free survival following peripheral DC vaccination with Liau et al. going into further detail describing their findings.
They reported that out of the 8 patients who underwent re-operation for progression, 4
survived for more than 30 months whilst 3 survived for less than a year and the remaining one had intermediate survival. The patients that survived more than 30 months had shown a robust CD3 and CD8 lymphocytic tumor infiltration that was not present in the pre-operative tissue samples. This infiltration was not observed in the tumor samples of the 3 patients who survived less than a year 29 .
Despite not directly correlating their outcomes with immune infiltration, all six remaining studies reported improved overall survival in the vaccination treatment group.
Overall survival varied from 348 to 1077 days for the vaccination group. In the studies of Yu, Liau, Steiner and Yamanaka, comparison with control groups was performed which showed statistically significant differences between the two groups. Most interestingly, Prins et al.
showed statistically significant improvement in overall survival, not only when comparing the vaccination group with the controls but also when comparing patients who received treatment at first diagnosis to those receiving treatment following recurrence (p=0.03) 26 .
( Table 3 ).
The most relevant prognostic factors described in these studies, in keeping with the existing literature on high grade gliomas, were patients' age, performance score and treatment protocols used. No information, however, was provided on other potentially relevant parameters such as tumor size, location or its molecular and genetic makeup.
Discussion
Immunotherapy for HGGs is a relatively new concept. Unlike HGGs, in other common types of cancer, such as ovarian, colorectal and melanoma, the presence of TILs is consistently related to better clinical outcome [31] [32] [33] [34] [35] [36] . The relevant literature on DCimmunotherapy for HGGs is still limited and therefore the number of studies included in our review is small, potentially limiting any didactic conclusions. Nonetheless, data provide indication of the types of lymphocytes that infiltrate malignant gliomas following patients with WHO grade III and IV gliomas, showed negative correlation between the presence of TILs and survival 41 . Furthermore, the teams of Schiffer and Rossi reported no correlation between infiltration and survival in their studies 42, 43 . Such observation is hard to explain but glioblastoma molecular heterogeneity, varying treatment and sampling protocols, as well as the lack of lymphocytic sub-type classification (CD4, CD8, T-reg) across studies could have potentially led to these contradicting results.
In our view, the small number of studies together with the relative lack of detailed description of prognostic factors limits any firm conclusions on the relevance of lymphocytic tumor infiltration to survival. The quality of the data and particularly its consistency across a range of studies reviewed here, does however raise the possibility that DC immunotherapy may improve patient outcomes, warranting further studies. It is important to highlight at this point the heterogeneity of the patients included in the mentioned studies. With the exception of two, the remaining included both patients with newly diagnosed and recurrent malignant gliomas with overall survival data referring to the combination of the groups. Subgroup analysis comparing recurrent to newly diagnosed disease was performed by two studies with contradicting results (Table 3) . Additionally, comparison with control groups is not the result of randomized trials but a comparison to matched or historical controls.
Furthermore, data regarding the safety of the technique is limited. Authors report that the technique was well tolerated with the most commonly reported adverse events being headaches, fever, myalgia, fatigue, lymphopenia and seizures, in a small number of patients and no author has reported any grade 3 or 4 National Cancer Institute Common Toxicity
Criteria adverse events. The above indicate that conclusions regarding survival rates, safety and recommendation or not of the technique cannot be safely drawn and that the results of ongoing phase III trials should be awaited.
Although it is well established that glioblastoma induces immunosuppression, the exact mechanisms and patient specific factors underlying those processes remain unclear.
Great emphasis is now given on the presence of T regulatory cells that have been shown to downregulate CD4 and CD8 cells and also produce IL-10 and TGB-b which block effector T cell response 44, 45 . Liau proposed that active tumor recurrence and/or bulky residual tumor further negatively influence the ability of T lymphocytes to accumulate within the local tumor microenvironment affecting infiltration following DC vaccination 22 . Notably, Yu implied that T cell infiltration is a characteristic of a subset of patients that undergo re-operation 25, 45 whereas Prins found a positive correlation between increased T lymphocytic infiltration and the mesenchymal gene expression 26 . Controversially, a recent study by Yang et al. showed that dendritic cells loaded with autologous tumor lysate increased tumor angiogenesis and indicated for the first time that the latter process could potentially promote tumor progression 46 . Of note though, the study was based on an animal model and there is no evidence to date indicating that similar findings would be expected in human cancer and more specifically glioblastoma. Nonetheless, the findings create an important question for future research.
The most important finding of this review is the wide variation in the degree of response to DC-immunotherapy measured by the increase in the numbers of infiltrating lymphocytes. The variations could arguably be attributed to the different protocols followed by each study group but there were significant differences even within individual studies with some patients exhibiting significant, some moderate and some no infiltration at all. 
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